Connect your AI

Stereotaxis STXS Operating Cash Flow

Operating Cash Flow at other companies

AbbottABT

$1.32B-7.2%

Boston ScientificBSX

$348M-35.7%

MedtronicMDT

$2.57B+1.8%

StrykerSYK

$581M+132%

ITG

Integer HoldingsITGR

$24.7M-21.0%

Merit Medical SystemsMMSI

$40.68M+0.3%

Other financials

Income statement

Revenue$6.3M-15.8%

Gross profit$3.8M-6.6%

Operating income-$6.0M-0.9%

Net income-$5.9M-0.7%

EPS (diluted)-$0.06+14.3%

Balance sheet

Cash & equivalents$14.6M+36.7%

Total debt$5.3M-10.0%

Total equity$14.4M+399%

Total assets$54.0M+18.2%

Cash flow

CapEx$79.0K—

Free cash flow-$3.5M—

Valuation

Market cap$168.11M-11.6%

Enterprise value$158.77M-15.9%

P/S5.4×-0.6×

Profitability

Gross margin53.9%+0.5pp

Operating margin-71%-14.0pp

Net margin-69.5%-13.7pp

FCF margin-35.5%-2.4pp

Returns & leverage

Return on equity-251.5%-29.9pp

Debt / equity0.4×-1.7×

Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Stereotaxis's operating cash flow?: Stereotaxis (STXS) reported operating cash flow of -$3.44M in Q1 2026.
How has Stereotaxis's operating cash flow changed year-over-year?: Stereotaxis's operating cash flow decreased by 93.5% year-over-year, from -$1.78M to -$3.44M.
What is the long-term trend for Stereotaxis's operating cash flow?: Over 3 years (2021 to 2025), Stereotaxis's operating cash flow has grown at a 66.2% compound annual growth rate (CAGR), from -$2.98M to -$13.69M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.